초록 ▼

The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit

The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen. The immunogenic peptide compositions of the present invention comprise immunogenic peptides having an HLA binding motif, where the peptide is from a target antigen. Target antigens of the present invention include prostate specific antigen (PSA), hepatitis B core and surface antigens (HBVc, HBVs) hepatitis C antigens, Epstein-Barr virus antigens, melanoma antigens (e.g., MAGE-1), human immunodeficiency virus (HIV) antigens, human papilloma virus (HPV) antigens, Lassa virus, mycobacterium tuberculosis (MT), p53, CEA, trypanosome surface antigen (TSA) and Her2/neu. An example of an immunogenic peptide of the present invention corresponds to a peptide less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, where the peptide comprises the p53 sequence SMPPPGTRV.

대표청구항 ▼

What is claimed is: 1. A composition comprising an immunogenic peptide of less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, wherein the peptide comprises the p53 sequence of SMPPPGTRV (SEQ ID NO:4). 2. The composition of claim 1, further comprising a pharmaceutica

What is claimed is: 1. A composition comprising an immunogenic peptide of less than about 15 amino acids in length that comprises an HLA-A2.1 binding motif, wherein the peptide comprises the p53 sequence of SMPPPGTRV (SEQ ID NO:4). 2. The composition of claim 1, further comprising a pharmaceutically acceptable carrier. 3. The composition of claim 1, further comprising a liposome.